Effect of OTX-101, a Novel Nanomicellar Formulation of Cyclosporine A, on Conjunctival Staining in Patients with Keratoconjunctivitis Sicca: A Pooled Analysis of Phase 2b/3 and 3 Clinical Trials.

Smyth-Medina, Robert

Effect of OTX-101, a Novel Nanomicellar Formulation of Cyclosporine A, on Conjunctival Staining in Patients with Keratoconjunctivitis Sicca: A Pooled Analysis of Phase 2b/3 and 3 Clinical Trials. [electronic resource] - Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics Sep 2019 - 388-394 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

1557-7732

10.1089/jop.2018.0154 doi


Clinical Trials, Phase II as Topic
Clinical Trials, Phase III as Topic
Cyclosporine--administration & dosage
Humans
Immunosuppressive Agents--administration & dosage
Keratoconjunctivitis Sicca--drug therapy
Micelles
Nanoparticles
Randomized Controlled Trials as Topic
Time Factors
Treatment Outcome